Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

2,000 publications—and counting

To date, over 2,000 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

JCO Cancer Clinical Informatics
March 2026
Ensuring reliability of curated EHR-derived data: The Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework
Estevez M, Singh N, Dyson L, et al.
JCO Cancer Clinical Informatics
March 2026
Impact of real-world response to first-line immunotherapy and chemotherapy on subsequent treatment outcomes in patients with advanced or metastatic non-small cell lung cancer
Malhotra J, Viswanathan S, Mhatre S, et al.
ASCO GU
February 2026
Persistent gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024)
McKay R, Li W, Roose J, et al.
ASCO GU
February 2026
Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with locally advanced/metastatic urothelial cancer
Smyth E, Richey M, Patel K, et al.
ASCO GU
February 2026
Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (rwOS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) with frailty or comorbidities
Grande E, Bamias A, Wit, R, et al.
ASCO GU
February 2026
Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment
Patel K, Zhao D, Hankinson E, et al.
ASCO GU
February 2026
Treatment patterns and survival outcomes among lutetium 177-experienced patients with metastatic castration-resistant prostate cancer
tran B, Dorff T, Richey M, et al.
ASCO GU
February 2026
Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations
Hankinson E, Kerr B, Ward P, et al.
DKK
February 2026
Validation of composite mortality data in electronic health records-derived data in Germany: Comparison to a German cancer registry
- Publication summary
- Publications

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Cookie Settings
© FLATIRON HEALTH® 2026